Moderna Surges on Surprise Profit and Increased Market Share

The biotech firm exceeds expectations with strategic shifts and a robust pipeline, eyeing regulatory approval for its RSV vaccine.

Moderna reports a surprise fourth-quarter profit, with shares surging due to increased U.S. COVID-19 vaccine market share and cost-cutting measures.
The company's revenue fell year-over-year but exceeded expectations, driven by deferred revenue and a strategic shift to a seasonal endemic market.
Moderna anticipates regulatory approval for its experimental RSV vaccine by May 12, aiming for sales gains and expansion into new markets.
Despite a net loss for the year, Moderna remains financially robust, with a focus on its late-stage pipeline, including a combined COVID and flu vaccine.
Moderna reaffirms its 2024 sales forecast of approximately $4 billion, reflecting the expected seasonality of respiratory vaccines.